glp 1 and potassium DPP4 Inhibitors vs GLP-1 Agonists | June 2021 | Clinical Corner Frontiers | GLP-1 Receptor Agonists

The Phase 2 SHAPE trial (NCT04831281) in Parkinsons disease dementia and dementia with Lewy bodies failed its primary endpoint in December 2023

and Moss, P., Canadian Journal of Psychiatry , 2012, vol

Additionally, the effects of carnitine on kidney function and renal safety should be carefully evaluated, especially in individuals with pre-existing kidney disease or those taking certain medications

Do reactive oxygen species play a role in myeloid leukemias

In the world of regenerative medicine, BPC-157, also known as Body Protection Compound-157, has emerged as a promising peptide with a myriad of potential benefits for human health